{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:26:55Z","timestamp":1792794415138,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1053\/j.seminoncol.2018.11.004","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T21:30:59Z","timestamp":1545341459000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer"],"prefix":"10.1053","volume":"46","author":[{"given":"Maria E.","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2018.11.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/618985","article-title":"Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease","volume":"2012","author":"Busaidy","year":"2012","journal-title":"J Thyroid Res"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0002","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1586\/eem.12.36","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions","volume":"7","author":"Pacini","year":"2012","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0003","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0004","series-title":"Thyroid carcinoma. Version 1","author":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)","year":"2018"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0005","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0006","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1634\/theoncologist.2014-0313","article-title":"Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients","volume":"20","author":"Gruber","year":"2015","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0009","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834014548188","article-title":"Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer","volume":"6","author":"Worden","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0010","unstructured":"Eisai Inc. Lenvima (lenvatinib) [prescribing information]. Eisai Inc., Woodcliff Lake, NJ, 2017."},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0011","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0012","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0013","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J Thyroid Res"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0016","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1158\/1078-0432.CCR-09-1980","article-title":"E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles","volume":"15","author":"Ikuta","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0017","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.2174\/1381612822666160614084943","article-title":"Effects and role of multikinase inhibitors in thyroid cancer","volume":"22","author":"Laursen","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0018","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0019","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/985780","article-title":"Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer","volume":"2011","author":"Cabanillas","year":"2011","journal-title":"J Thyroid Res"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0020","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-fefractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","article-title":"Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes","volume":"56","author":"Haddad","year":"2017","journal-title":"Endocrine"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2018.11.004_bib0022","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.01.001","article-title":"Management of sorafenib-related adverse events: a clinician's perspective","volume":"41","author":"Brose","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0023","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0024","first-page":"2435","article-title":"Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer","volume":"8","author":"Chrisoulidou","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0025","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4158\/EP171822.OR","article-title":"Optimizing lenvatinib therapy in patients with metastatic radioactive iodine-resistant differentiated thyroid cancers","volume":"23","author":"Jasim","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0026","first-page":"534","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0027","first-page":"6","article-title":"Hypertension in cancer patients treated with anti-angiogenic based regimens","volume":"1","author":"Wasserstrum","year":"2015","journal-title":"Cardiooncology"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0028","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0029","doi-asserted-by":"crossref","first-page":"E1736","DOI":"10.3390\/ijms18081736","article-title":"Hypertension caused by lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Bendtsen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-013-2339-y","article-title":"A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)","volume":"73","author":"Molina","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0031","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0032","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/cncr.31344","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0033","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/cas.12826","article-title":"Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Kiyota","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0034","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.3390\/ijms18030625","article-title":"The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors","volume":"18","author":"Ancker","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2017.03.039","article-title":"Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction","volume":"260","author":"Sueta","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0036","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0037","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0038","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2011.03.033","article-title":"The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer","volume":"47","author":"Bamias","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0039","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41199-017-0026-0","article-title":"Optimal use of lenvatinib in the treatment of advanced thyroid cancer","volume":"2","author":"Takahashi","year":"2017","journal-title":"Cancers Head Neck"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0041","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0042","series-title":"Cancer-related fatigue. Version 2","author":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)","year":"2018"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0043","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/djr511","article-title":"Targeted therapies for renal cell carcinoma: review of adverse event management strategies","volume":"104","author":"Eisen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0044","article-title":"Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice","author":"Berdelou","year":"2017","journal-title":"Thyroid"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00228-017-2299-y","article-title":"Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials","volume":"73","author":"Li","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0046","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajco.12687","article-title":"Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities","volume":"14","author":"Aw","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0047","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s10637-012-9796-8","article-title":"Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities","volume":"30","author":"Cohen","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0048","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","article-title":"Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors","volume":"15","author":"Pilotte","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0049","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0050","first-page":"2","article-title":"Updates in the use of the mTOR inhibitor everolimus in advanced breast cancer","volume":"1","author":"Anderson","year":"2016","journal-title":"J Cancer Clin Trials"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0051","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1089\/thy.2013.0700","article-title":"Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer","volume":"24","author":"Lacouture","year":"2014","journal-title":"Thyroid"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0052","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0053","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0054","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/neuonc\/nor223","article-title":"Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors","volume":"14","author":"Armstrong","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12957-017-1096-5","article-title":"Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report","volume":"15","author":"Kitamura","year":"2017","journal-title":"World J Surg Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0056","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0057","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1464-410X.2010.09357.x","article-title":"Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery","volume":"106","author":"Silberstein","year":"2010","journal-title":"BJU Int"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0058","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.18632\/oncotarget.10019","article-title":"Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0059","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0060","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3324\/haematol.2009.020958","article-title":"Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k\/Akt pathway","volume":"95","author":"Ye","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0061","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0062","first-page":"395","article-title":"Cabozantinib for progressive metastatic medullary thyroid cancer: a review","volume":"10","author":"Colombo","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0063","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10456-010-9197-6","article-title":"Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review","volume":"14","author":"Walraven","year":"2011","journal-title":"Angiogenesis"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0064","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(09)70362-6","article-title":"Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer","volume":"11","author":"Stone","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0065","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.critrevonc.2013.10.002","article-title":"Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"89","author":"Qi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0066","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2009.24.7353","article-title":"Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab","volume":"28","author":"Spigel","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0067","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1089\/thy.2012.0598","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins","year":"2014","journal-title":"Thyroid"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0068","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1445-5994.2004.00750.x","article-title":"Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed","volume":"35","author":"Stott","year":"2005","journal-title":"Intern Med J"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0069","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archneur.63.10.1475","article-title":"Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer","volume":"63","author":"Allen","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/qjmed\/hcr139","article-title":"Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment","volume":"105","author":"Seet","year":"2012","journal-title":"QJM"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0071","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4065\/mcp.2009.0590","article-title":"Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings","volume":"85","author":"Fugate","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0072","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-011-0201-x","article-title":"Posterior reversible encephalopathy syndrome induced by anti-VEGF agents","volume":"6","author":"Tlemsani","year":"2011","journal-title":"Target Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0073","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3747\/pdi.2012.00152","article-title":"Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness","volume":"32","author":"Hobson","year":"2012","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0074","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/epi.12933","article-title":"Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome","volume":"56","author":"Datar","year":"2015","journal-title":"Epilepsia"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0075","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.51.5.1369","article-title":"Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI","volume":"51","author":"Ay","year":"1998","journal-title":"Neurology"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0076","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0077","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","article-title":"The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors","volume":"15","author":"Tocchetti","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0078","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-211522","article-title":"Rapid and fatal acute heart failure induced by pazopanib","volume":"2015","author":"van Marcke","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0079","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14740338.2013.788642","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors","volume":"12","author":"Mouhayar","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0081","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2018.11.004_bib0082","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf [Accessed October 3, 2018]."}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418302203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418302203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:50Z","timestamp":1758804890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775418302203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0093775418302203"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.11.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}